Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

@article{Lee2016CirculatingIC,
  title={Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma},
  author={Sung-Eun Lee and Ji-Young Lim and Da-Bin Ryu and Tae Woo Kim and Jae-Ho Yoon and B. Cho and Ki-Seong Eom and Yoo-Jin Kim and Hee-Je Kim and Seok Jong Lee and Seok-Goo Cho and Dong-wook Kim and Jong-Wook Lee and Woo-Sung Min and Myungshin Kim and Chang-Ki Min},
  journal={Cancer Immunology, Immunotherapy},
  year={2016},
  volume={65},
  pages={983-994}
}
Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear. In this study, we analyzed the association between immune cell populations and clinical outcomes in patients receiving Len-dex for the treatment of RRMM. Peripheral blood samples from 90 RRMM patients were taken on day… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 1 EXCERPT

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 1 EXCERPT